Kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9758521-B2
Application number	US-201615388178-A
Country	US
Kind code	B2
Filing date	Dec 22, 2016
Priority date	Dec 23, 2015
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

Compounds of formulae (I), (II), and (III), defined herein, are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

First claim

The invention claimed is:

1. A compound of formula (I):

wherein
R 1 is a group of one of the following formulae:

or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt according to claim 1 , which is:
1-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalenyl}-urea hydrochloride salt;
1-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalenyl}-urea hydrochloride salt;
1-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalenyl}-urea hydrochloride salt; or
1-(3-tert-Butyl-1′-methyl-1′H-[1,4′]bipyrazolyl-5-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-piperidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea hydrochloride salt.

3. A compound of formula (II):

wherein
R 1 is a group of one of the following formulae:

or a pharmaceutically acceptable salt thereof.

4. A compound or pharmaceutically acceptable salt according to claim 3 , which is:
1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1,2-dimethyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea hydrochloride salt; or
1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(1-dimethylamino-1-methyl-ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea hydrochloride salt.

5. A compound of formula (III):

wherein
R 1 is a group of one of the following formulae:

or a pharmaceutically acceptable salt thereof.

6. A compound or pharmaceutically acceptable salt according to claim 5 , which is:
1-(5-tert Butyl-isoxazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-isopropyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl)}-urea hydrochloride salt; or
1-(5-tert Butyl-isoxazol-3-yl)-3-{(1S,4R)-4-[3-((S)-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea hydrochloride salt.

7. A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt according to claim 1 and one or more pharmaceutically acceptable carriers.

Assignees

• Chiesi Farm Spa

Inventors

• Capaldi Carmelida
• Armani Elisabetta
• Jennings Andrew Steven Robert
• Hurley Christopher

Classifications

• A61P11/06

  Antiasthmatics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title